Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements match provided labeling (e.g., dosing with/without food, grapefruit juice interaction, muscle risk). However, multiple claims about avocado specifically and several generalizations (food absorption effects, adherence/symptom patterning, and interaction examples) are not supported by the provided FDA label excerpts.
Category Scores
Accurate Statements
Lipitor can be taken with or without food.
Label excerpt 2.1: “LIPITOR can be administered as a single dose at any time of the day, with or without food…”
Grapefruit and grapefruit juice can raise levels of some statins.
Label excerpt 7.2 Grapefruit Juice: “Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin…”
Statin-related muscle effects are a known risk regardless of food.
Label excerpt 5.1 Skeletal Muscle: “Atorvastatin, like other statins, occasionally causes myopathy…” and “Rare cases of rhabdomyolysis…” (food not mentioned).
Other medicines that can raise statin levels (for example, certain antibiotics/antifungals, HIV antivirals, or some transplant medications) may interact with statins.
Label excerpt 7: “The risk of myopathy… is increased with concurrent administration of… cyclosporine, or strong CYP 3A4 inhibitors…” and excerpt 7.1/7.2: strong CYP 3A4 inhibitors increase atorvastatin concentrations.
Unsupported Statements
There is no well-known, clinically important drug–food interaction between Lipitor (atorvastatin) and avocado.
Provided FDA label excerpts do not mention avocado or state that it has no clinically important interaction.
Avocado is not known to contain the same types of compounds that commonly raise statin blood levels (for example, certain grapefruit components or specific medications).
No avocado-specific content is present in the provided label excerpts.
Foods can slightly change how quickly a medicine is absorbed.
The provided label excerpt about food (12.3) indicates decreases in rate and extent of absorption, but the statement is broad and not tied to atorvastatin specifically in the excerpts provided beyond general PK wording; no explicit “slightly” or general food statement appears.
Atorvastatin’s effect is usually not meaningfully altered by typical foods.
Label excerpt 12.3 states “LDL-C reduction is similar whether LIPITOR is given with or without food,” but does not support the phrasing “usually not meaningfully altered” regarding typical foods beyond that.
Avocado has not been flagged as a problematic food with atorvastatin.
No provided label excerpt addresses avocado or whether it is flagged as problematic.
New muscle pain or weakness after taking Lipitor and eating avocado should be reported to a clinician promptly.
The provided excerpts describe myopathy/rhabdomyolysis risk and that therapy should be withheld/discontinued in acute serious myopathy, but do not include avocado-specific symptom timing or an instruction to report symptoms promptly.
Avocado is not in the same category as grapefruit for interactions that raise statin levels.
No avocado-specific interaction classification is present in the provided label excerpts.
Taking Lipitor consistently at the same time each day helps with adherence.
No adherence guidance or “same time” instruction is included in the provided label excerpts.
Taking Lipitor consistently makes it easier to notice any pattern between symptoms and what you eat.
No labeling content supports symptom/food patterning guidance.
Grapefruit and grapefruit juice can raise levels of some statins.
This is only partially supported for LIPITOR/atorvastatin specifically by the provided label. The statement refers generally to “some statins,” which is broader than the provided atorvastatin-specific excerpt.
Contradictions
Important Omissions
No mention that LIPITOR dosing/interactions guidance in label is specific to strong CYP 3A4 inhibitors (with cautions by drug and dose thresholds) and grapefruit juice amount (e.g., excessive >1.2 liters/day in the provided excerpt).
Importance:
Moderate
No mention that LIPITOR should be temporarily withheld or discontinued in patients with an acute, serious condition suggestive of myopathy.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Avocado-specific interaction claims are unsupported by the provided label excerpts and could mislead regarding interaction risk. Several general guidance statements (adherence/symptom patterning and symptom reporting tied to avocado) are not supported by the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple statements about avocado interactions and adherence/symptom-patterning are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or qualify all avocado-specific interaction assertions unless supported by label; align food discussion strictly with provided label excerpts (with/without food PK effect and grapefruit juice CYP3A4 inhibition/amount). Use only label-supported muscle safety language (myopathy/rhabdomyolysis risk and temporarily withholding/discontinuing in acute serious myopathy).